PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8661368-10	1996	Pulsed VT (8 to 48 hr) or cycloheximide (4 to 48 hr) exposure of CD4(+) cells enhanced supernatant levels of IL-2 but not IL-4 upon incubation for 24 hr in fresh medium.	Cycloheximide	26-39	interleukin 4	Mus musculus	122-126	
14500682-5	2003	Cycloheximide as well as sodium cromoglycate blocked the Der f-induced IL-4 production, indicating a de novo protein synthesis process.	Cycloheximide	0-13	interleukin 4	Mus musculus	71-75	
11859138-6	2002	Second, the ability of IL-4 to potentiate LPS-stimulated cytokine production appears to require new IL-4-stimulated gene expression, because it is time dependent, requires the activation of STAT6, and is blocked by the reversible protein synthesis inhibitor cycloheximide during the IL-4 pretreatment period.	Cycloheximide	258-271	interleukin 4	Mus musculus	23-27	
11859138-6	2002	Second, the ability of IL-4 to potentiate LPS-stimulated cytokine production appears to require new IL-4-stimulated gene expression, because it is time dependent, requires the activation of STAT6, and is blocked by the reversible protein synthesis inhibitor cycloheximide during the IL-4 pretreatment period.	Cycloheximide	258-271	interleukin 4	Mus musculus	100-104	
11859138-6	2002	Second, the ability of IL-4 to potentiate LPS-stimulated cytokine production appears to require new IL-4-stimulated gene expression, because it is time dependent, requires the activation of STAT6, and is blocked by the reversible protein synthesis inhibitor cycloheximide during the IL-4 pretreatment period.	Cycloheximide	258-271	interleukin 4	Mus musculus	100-104	
9122225-6	1997	B cells, but not T cells or mast cells, express Fig1 in response to IL-4 within 2 hr in a cycloheximide resistant manner.	Cycloheximide	90-103	interleukin 4	Mus musculus	68-72	
8658534-11	1996	Pulsed VT (8 to 48 hr) or cycloheximide (4 to 48 hr) exposure of CD4+ cells enhanced supernatant levels of IL-2 but not IL-4 upon incubation for 24 hr in fresh medium.	Cycloheximide	26-39	interleukin 4	Mus musculus	120-124	
2142529-9	1990	Effects of cyclosporine A and the protein synthesis inhibitors cycloheximide and anisomycin on IL-4 and IL-5 gene expression suggest that these genes are activated by different pathways after anti-CD3 stimulation.	Cycloheximide	63-76	interleukin 4	Mus musculus	95-99	
8852946-6	1996	The inhibition of PGHS-2 and cPLA2 mRNA expression by IL-4 (10 ng/ml) was present at 1 h, reached a maximum at 4 h, and persisted for 24 h. The effects were maintained in the presence of cycloheximide.	Cycloheximide	187-200	interleukin 4	Mus musculus	54-58	
7768303-9	1995	TGF-beta 1- and IL-4-mediated augmentation of MCP-1/JE mRNA by IL-1 alpha or IFN-gamma was partially reversed by cycloheximide (CHX), whereas potentiation of IP-10 by either modulator remained unaffected.	Cycloheximide	113-126	interleukin 4	Mus musculus	16-20	
7768303-9	1995	TGF-beta 1- and IL-4-mediated augmentation of MCP-1/JE mRNA by IL-1 alpha or IFN-gamma was partially reversed by cycloheximide (CHX), whereas potentiation of IP-10 by either modulator remained unaffected.	Cycloheximide	128-131	interleukin 4	Mus musculus	16-20	
8061119-4	1994	The data show that incubation with IL-4 results in a dose-dependent, 2-3 x increase in M-CSFr with no change in binding affinity and a maximal effect on binding at about 12 h. This increase in M-CSFr is dependent upon new, specific protein synthesis as shown by the inhibitory action of cycloheximide, and gel analysis of radiolabeled, specific protein, immunoprecipitated with anti-M-CSFr antibody.	Cycloheximide	287-300	interleukin 4	Mus musculus	35-39	
1531844-7	1992	Treatment of IFN-gamma/IL-2-stimulated macrophages with cycloheximide blocks the suppressive effect of IL-4, suggesting that de novo synthesis of an intermediate protein is part of the suppressive mechanism.	Cycloheximide	56-69	interleukin 4	Mus musculus	103-107	
2140531-5	1990	The Ia-inductive effects of both IL-4 and IgE-antigen complexes were inhibited by cycloheximide and actinomycin-D.	Cycloheximide	82-95	interleukin 4	Mus musculus	33-37	
2140531-6	1990	However, whereas actinomycin-D and cycloheximide blocked IL-4 induction of Fc epsilon RII expression, inhibition of transcription or protein synthesis did not abrogate the increased expression of Fc epsilon R associated with IgE-antigen complexes.	Cycloheximide	35-48	interleukin 4	Mus musculus	57-61	
8459105-11	1993	Addition of cycloheximide (50 micrograms/ml) inhibited formation of IL-2, IL-4 and IL-6 SFC by approximately 90%.	Cycloheximide	12-25	interleukin 4	Mus musculus	74-78